Medaxone

Ceftriaxone, the active ingredient in Medaxone, is a third‑generation cephalosporin presented as a sterile powder for injection for intramuscular and intravenous use. It treats a broad range of susceptible bacterial infections in adults and children, including pneumonia, meningitis, gonorrhea, urinary tract infections, and skin or soft‑tissue infections.

GNH USA supplies Medaxone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat infections caused by susceptible bacteria.

- Pneumonia: achieves clinical cure of community‑acquired and hospital‑acquired pneumonia. - Meningitis: provides rapid bacterial eradication and reduces mortality in bacterial meningitis. - Gonorrhea: eliminates Neisseria gonorrhoeae infection and prevents complications. - Urinary tract infection: resolves infection and alleviates symptoms in uncomplicated and complicated UTIs. - Skin and soft‑tissue infection: clears infection and promotes healing in cellulitis and wound infections.

Ceftriaxone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Injection site pain: discomfort at the site of intramuscular or intravenous administration. - Diarrhea: mild to moderate loose stools. - Rash: erythematous skin eruption. - Nausea: feeling of queasiness. - Vomiting: expulsion of stomach contents. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment. - Hemolytic anemia: destruction of red blood cells. - Thrombophlebitis: inflammation of veins at the injection site. - Calcium precipitation: risk of insoluble complexes when mixed with calcium‑containing solutions.

Ceftriaxone requires careful consideration of patient‑specific factors before use.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: observe liver enzymes during prolonged treatment. - Neonates (≤28 days) and infants (≤3 months) with hyperbilirubinemia: avoid due to risk of bilirubin displacement. - Pregnancy and breastfeeding: use only if clearly indicated after risk‑benefit assessment. - Known β‑lactam allergy: contraindicated in patients with hypersensitivity to cephalosporins or penicillins. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Ceftriaxone can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Calcium‑containing IV solutions: may precipitate insoluble calcium‑ceftriaxone complexes. - Warfarin: can enhance anticoagulant effect, increasing bleeding risk. - Aminoglycosides: combined use may increase nephrotoxicity. - Live vaccines: may reduce vaccine efficacy. - Diuretics (e.g., furosemide): can exacerbate calcium precipitation risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive effectiveness. - Probenecid: may increase ceftriaxone plasma concentrations. - Other nephrotoxic agents (e.g., vancomycin): monitor renal function. - Antacids containing aluminum or magnesium: may affect absorption if given orally (rarely applicable).